The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Matt you are right; the most interesting thing at the results will be the impact of the Siemens Troponin revenues and their potential going forward. Given the announcement by Siemens regarding Troponin in May, I would hope that its use would have ramped up sufficiently in the short term to cover the revenues of the licence that is expiring. With the share price gains recently someone must be confident.
Terrific news. Of course no indication yet on whether the new troponin revenues will offset the license which is finishing this month.
"The Board is pleased to report that revenues for the financial year ended 30 June 2017 are expected to be marginally in excess of £7M (2015/16: £5.5M). Since the cost-base of the Company continues to follow a similar shallow trajectory as in previous years, both revenues and profits before tax are expected to be ahead of market expectations for the year ended 30 June 2017." Once again, excellent news. I think the share price is up with events but I continue to hold this solid company as I believe it will do well long term.
Hi Azurite - yes, things going well in my healthcare stocks at the moment. Not so good in technology unfortunately....;0-))
Hi Mick - you remember correctly - I'll check the Board now.
Some biggish buys going through - I wonder if UK BUFFETTOLOGY FUND are adding to their already sizeable holding as they are expecting the up and coming trading statement to be positive with news on when the Troponin sales will begin.
Matt, good to see a fellow HCM investor here.
matt have you seen my messages on the prg bb? , i think i remember your monicker from way back , if i`m wrong apologies
...but this stock has become a major holding for me here, and I'm taking some profits and recycling into Glaxo and Astra which have been weakish lately. Will still retain most of my holding here though.
This is a share you buy and hold. It meets all the requirements of a Buffett stock; has a moat around the business that is a barrier to new entrants, a long term tied in customer base, rising profits and dividends. What's not to like? Only wished I had bought more at around £7 (my first entry into this). Seems to be rising in anticipation of the trading statement.
Over £20 again with the UK BUFFETTOLOGY FUND recently increasing its stake to 7.3%. A trading statement should be due this month and it will be interesting to hear news about Siemens Troponin and when its revenues kick in. Wild cards could be progress with CardiNor or Pre Diagnostics.
Over £20 today - Profit talking anyone...?
Yep - it'll be interesting to see how quickly they can ramp this up. BVXP have intimated that the stock is already with customers ready to go, and it's simply a matter of telling them to start using it! We'll see.
I notice that the company have now acknowledged the announcement from Siemens yesterday. More importantly they have stressed the importance to their revenues going forward.
Looks like Siemens Troponin test is now available in Europe, see announcement from Siemens https://goo.gl/yKRRc8
....and more importantly, seems to be no shift in view on the Siemens Troponin test launch date and it's ability to replace the revenue being lost from September.
Bioventix's increases profit in second half of 2016 http://bit.ly/2n8DtSc
That was the view expressed by Peter H in a presentation he did last year; he comes across as someone who does not over promise and tries to manage shareholder expectations. In the same presentation he tried to play down the recent investment in CardiNor ( Secretoneurin (SN) IVD test aimed at the estimated USD 4 billion cardiovascular risk assessment market, the assay is intended for launch in early 2017. ) and collaboration with Pre Diagnostics for a Alzheimer's test (research only test in 2017). These are massive markets and if either one comes off then it will be massive for the company. None of this is priced in.
That was the view expressed by Peter H in a presentation he did last year; he comes across as someone who does not over promise and tries to manage shareholder expectations. In the same presentation he tried to play down the recent investment in CardiNor ( Secretoneurin (SN) IVD test aimed at the estimated USD 4 billion cardiovascular risk assessment market, the assay is intended for launch in early 2017. ) and collaboration with Pre Diagnostics for a Alzheimer's test (research only test in 2017). These are massive markets and if either one comes off then it will be massive for the company. None of this is priced in.
I'm hoping they'll be available some time before then. Roche's already has approval I believe, whilst the large loss of the other revenue source happens in September....
Interims out soon so hopefully we will get an update. There was hope that the Tropins tests would be available during the summer of 2017
...continues to fly, but when will we see the new Siemens Troponin test!!! Clock is ticking....
FDA cleared the first in a new generation of cardiac troponin T (TnT) blood tests for rapid diagnosis of acute MI, Roche's Elecsys TnT Gen 5 STAT test. see http://www.medpagetoday.com/cardiology/myocardialinfarction/62620 This should make it easier for Siemens to get approval in the US for their equivalent Troponin tests using Bioventix antibodies. Approval in Europe for Siemens is due mid 2017 and revenues could be worth 700-800k in 2016/2017 and grow to over £2m/annum in a few years so this a key antibody for Bioventix. Notice the share drifting higher so I wonder if people are waking up to this opportunity.
in the youtube video Peter Harrison, CEO, talks through the latest FY results 30 June 2016 with @tamzinpiworld. He expands on the success of Vitamin D and its future prospects, together with the positive impact of foreign exchange. He goes on to talk about the NT proBNP licence, which comes to an end July 2017, with all revenue (c.£750k) being lost from August 2017 onwards. Peter is confident Troponin, will launch at some point in 2017, based on all the updates given by Siemens, although timing is in Siemen’s hand. He has estimated July 2017 to start roll-out, it being the mid point of the year. He mentions the initial and on-going revenue expectations for Troponin. Peter briefly discusses other antibodies already producing revenue, and future developments for the medium term. Cardinor, Norway is not discussed, since this is unlikely to result in revenues over the near term. Peter answers questions on a few potential threats, including consolidation of customers and any new technologies that could disrupt their market. Finally, he talks about staff motivation, and financial reward. Presentation slides can be downloaded at: http://www.piworld.co.uk/company-vide..
See video by CEO on youtube https://www.youtube.com/watch?v=81S9H7ymim0 I hold btw